Seminoma
18
8
15
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
5.6%
1 terminated out of 18 trials
50.0%
-36.5% vs benchmark
11%
2 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (18)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
PRISTINE Trial: PRoton Beam Therapy In Seminoma - Toxicity INvestigation and Evaluation of Outcome
Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer
A Study of miRNA 371 in Patients With Germ Cell Tumors
THERApy De-escalation for TESTicular Cancer
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND
Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer
Therapy De-escalation in Seminoma Stage IIA/B
Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma
De-escalation Study for Stage IIa/IIb < 3 cm Seminoma
MicroRNA as Markers in Testicular Cancer
Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients